Get superior transfection for your gene knockdown studies

Lipofectamine® RNAiMAX Transfection Reagent offers an advanced, efficient solution for siRNA delivery. No other siRNA specific transfection reagent provides such easy and efficient siRNA delivery in a wide variety of cell lines including common cell types, stem cells and primary cells, as well as traditionally hard-to-transfect cell types.

  • Unmatched performance, delivering greater knockdown with less siRNA
  • Easy optimization with a simple protocol helps ensure great performance

Video protocol: siRNA transfection


    

View the video to see the steps needed to perform siRNA transfection with Lipofectamine® RNAiMAX reagent.

siRNA transfection protocol

Superior transfection at low siRNA concentrations

When it comes to achieving effective gene knockdown, Lipofectamine® RNAiMAX Transfection Reagent easily outperforms other siRNA transfection reagents. High knockdown levels of target genes can be achieved with as little as 1 nM siRNA (Figure 1). The Lipofectamine® RNAiMAX protocol recommends using 10 nM siRNA as a starting point to maximize knockdown levels.

Superior knockdown with Lipofectamine

Figure 1. Superior knockdown with Lipofectamine® RNAiMAX Transfection Reagent compared to competing siRNA transfection reagents. At both 10 nM and 1 nM p53 siRNA, Lipofectamine® RNAiMAX Transfection Reagent provides more effective knockdown relative to nontransfected cells than other RNAi reagents, including siLentFect™ (Bio-Rad), DharmaFECT™ (Dharmacon), and HiPerFect (Qiagen) reagents.

Low cytotoxicity profile for easy optimization

Lipofectamine® RNAiMAX Transfection Reagent gives maximal knockdown and excellent cell viability across a 10-fold concentration range of the reagent (Figure 2). This makes Lipofectamine® RNAiMAX reagent easy to optimize for the lowest siRNA concentration while reducing cytotoxicity in your experimental system. Transfection-mediated cytotoxicity can mask the true phenotype of a target gene being studied, so minimizing the amount of reagent used in your transfections is a critical factor for successful RNAi experiments.

Optimal knockdown and minimal cytotoxicity in A549 cells transfected with Lipofectamine™ RNAiMAX Transfection Reagent.

Figure 2. Optimal knockdown and minimal cytotoxicity in A549 cells transfected with Lipofectamine® RNAiMAX Transfection Reagent. A range of 0.1 μL to 1.0 μL of Lipofectamine® RNAiMAX reagent was used, resulting in efficient knockdown of the p53 gene expression level while maintaining excellent cell viability.

Simple protocol for easy optimization in a broad spectrum of cell lines

With its ability to transfect a broad range of cell types, Lipofectamine® RNAiMAX reagent, combined with the BLOCK-iT™ Alexa Fluor® Red Fluorescent Control, gives you the most versatile approach to all of your knockdown experiments (Table 1, Figure 3). Lipofectamine® RNAiMAX offers a simple protocol—no need to remove transfection complexes, or change or add medium following transfection. You’ll spend less hands-on time and get results faster.

Table 1. Achieve transfection perfection on a wide range of cell types with Lipofectamine® RNAiMAX Transfection Reagent.

Cell line/type Cell type
MDA-MB-435 Breast cancer
HeLa Cervical carcinoma
HT1080 Human fibrosarcoma
A549 Lung carcinoma
HepG2 Liver carcinoma
MCF7 Breast cancer
SK-N-SH Neuroblastoma
Mesenchymal stem cells Bone marrow
HAMSC Human aortic smooth muscle cells
HEKa Human epidermal keratinocytes
HRE Human renal epithelial cells
NTERA-2 Embryonal carcinoma cells
HUVEC Human umbilical vein endothelial cells
ADSC Adipose-derived stem cells
HCT116 Colon carcinoma

Improve your transfection efficiencies using the BLOCK-iT™ Alexa Fluor® Red Fluorescent Control.

Figure 3. Improve your transfection efficiencies using the BLOCK-iT™ Alexa Fluor® Red Fluorescent Control. HeLa cells were transfected with the BLOCK-iT™ Alexa Fluor® Red Fluorescent Control (50 nM) using Lipofectamine® RNAiMAX Transfection Reagent. A. Twenty-four hours after transfection, nearly 100% of the cells take up the control and retain a normal morphology as seen in the bright-field image. B.